2089461-55-0
Chemical Structure
3'OMe-m7GpppAmpG
Synonym(s): m7(3'OMeG)(5')ppp(5')(2'OMeA)pG
- CAS No.: 2089461-55-0
- Formula:C33H45N15O24P4
- Molecular Weight:1159.69
IUPAC Name: 2-amino-9-((2R,3R,4S,5R)-5-((((((((((2R,3R,4R,5R)-3-(((((2R,3S,4R,5R)-5-(2-amino-6-oxo-3,6-dihydro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)-5-(6-amino-9H-purin-9-yl)-4-methoxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)(l1-oxidanyl)phosphoryl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-7-methyl-6-oxo-6,9-dihydro-3H-purin-7-ium
InChIKey: QLKZOMAEOBMBOC-RKTALREWSA-N
SMILES: O[C@@H]1[C@H](OC)[C@@H](COP(OP(OP(OC[C@@H]2[C@@H](OP([O-])(OC[C@@H]3[C@@H](O)[C@@H](O)[C@H](N4C(N=C(N)NC5=O)=C5N=C4)O3)=O)[C@@H](OC)[C@H](N6C(N=CN=C7N)=C7N=C6)O2)(O)=O)(O)=O)(O)=O)O[C@H]1N8C(N=C(N)NC9=O)=C9[N+](C)=C8
Biological Activity: 3’OMe-m7GpppAmpG (m7(3'OMeG)(5')ppp(5')(2'OMeA)pG) is a trinucleotide Cap1 analog with the structure m7 (3'OMeG)(5') ppp (5')(2'OMeA) pG, and also functions as a cis-acting ligase ribozyme inhibitor. 3’OMe-m7GpppAmpG effectively reduces free 5'-triphosphate groups on RNA transcripts, thereby enabling efficient co-transcriptional capping of in vitro transcribed mRNA. 3’OMe-m7GpppAmpG is not only widely used in the preparation of modified mRNA including trivalent influenza vaccine candidates, but also applicable to studies related to SARS-CoV-2 infection and other relevant research[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
3'OMe-m7GpppAmpG | 3’OMe-m7GpppAmpG (m7(3'OMeG)(5')ppp(5')(2'OMeA)pG) is a trinucleotide Cap1 analog with the structure m7 (3'OMeG)(5') ppp (5')(2'OMeA) pG, and also functions as a cis-acting ligase ribozyme inhibitor. 3’OMe-m7GpppAmpG effectively reduces free 5'-triphosphate groups on RNA transcripts, thereby enabling efficient co-transcriptional capping of in vitro transcribed mRNA. 3’OMe-m7GpppAmpG is not only widely used in the preparation of modified mRNA including trivalent influenza vaccine candidates, but also applicable to studies related to SARS-CoV-2 infection and other relevant research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Mazunina EP, et al. Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response. Front Immunol. 2024;15:1381508. Published 2024 Apr 16. [Content Brief]
- [2]. Su C I, et al. A cis-acting ligase ribozyme generates circular RNA in vitro for ectopic protein functioning[J]. Nature Communications, 2024, 15(1): 6607.
- [3]. Tusup M, et al. Design of in vitro transcribed mRNA vectors for research and therapy[J]. Chimia, 2019, 73(5): 391-391.
- [4]. Kim S, et al. Innate immune responses against mRNA vaccine promote cellular immunity through IFN-β at the injection site[J]. Nature communications, 2024, 15(1): 7226.
